At OncoCell MDx, we are answering the challenge of putting more in-depth information about disease pathology into physician and patient hands by delivering tools that optimally stratify disease. The company was founded around an immunogenomic platform invented at Harvard Medical School, in which gene expression patterns of white blood cells are interrogated after a noninvasive blood draw is taken from a patient. Leveraging a proprietary algorithm, the assay provides real surveillance of immune response changes, identifies the cause of disease, and filters out non-relevant noise. Our mission is to help patients live higher quality lives by providing highly accurate, less painful ways to screen, diagnose, and monitor prostate cancer and other diseases.
I joined OncoCell MDx in late April with the goal to leverage my expertise in cancer, genetics, molecular diagnostics and team building to create a special company. I’m here with some of the best respected names in diagnostics and in oncology. I was fortunate to bring over Chris Thibodeau to the team earlier this month, along with Dr. Kirk Wojno, a key opinion leader in prostate cancer diagnosis. Marc Stapley just joined our Board of Directors, and Geff Erickson, a Founder and longtime contributor to the company, will be staying on to lead Corporate Development and investor outreach. I look forward to working together with my team to make a global impact addressing clinical, operational and cost issues in disease diagnosis.
In the coming year, we will launch our first product, a unique assay that uses a simple blood draw to detect, grade and understand the aggressiveness of prostate cancer. Our goal is to immediately reduce the frequency of – and eventually replace – invasive, expensive and imprecise diagnostic procedures. We endeavor to help physicians make better and more timely decisions about who and how to treat, preclude over treatment, potentially reduce deaths related to under treatment, and ultimately enhance the effectiveness of treatment. In so doing, we aim to give patients their lives back. And while our approach is to always prioritize the highest value immediate opportunity, we’re also leveraging the platform to develop new assays for other cancers and disease. We’ve amassed a broad IP portfolio, including rights from Harvard to 45 issued patents and more than 100 pending applications in the United States and internationally. These issued and pending patents cover various aspects of our technology in numerous clinical indications including cancer, cardiovascular, infectious, and neurodegenerative disease, and immune- and kidney-related diseases.
To make manifest our mission to develop and deliver transformational solutions that improve lives, we need dedicated, engaged people organized around an audacious purpose and game changing technology. We have that here at OncoCell MDx and I’m privileged and excited to lead this highly skilled, highly motivated team into our next stage of clinical and corporate development.
I look forward to keeping you apprised of our progress.